A novel fat-loss + muscle-preserving strategy in obesity May redefine metabolic obesity treatment goals beyond GLP-1s Watch this space: Combining GLP-1s + ActRII blockers could be the future of metabolic therapy Update from #ADA2025 : Bimagrumab Bimagrumab Targets Activin Pathway in Obesity Dual Action Molecule #ADA2025 #Obesity #WeightLoss What is Bimagrumab
Diabetes Therapy 12(1):143157 Mohamed S, Le Bars S (2024) and E
If you want a step-by-step look at injection technique for a similar medication, our How to Take Tirzepatide Injection: A Step-by-Step Guide article is a useful reference
(2001) study tested intravenous ipamorelin in patients undergoing abdominal surgery
It names a lipid panel, fasting glucose, and kidney function as the initial labs that identify contraindications and establish metabolic context
After around a year, the participants who had gone on orforglipron tended to maintain more of their weight lossabout 79 percent of what they had lost on semaglutide and 75 percent of what theyd lost on tirzepatidethan the placebo group
